Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $1.54, $0.49 better than the analyst estimate of $1.05. Revenue for the quarter came in at $498.8 million versus the consensus estimate of $478.85 million.

GUIDANCE:

Neurocrine Biosciences sees FY2023 revenue of $1.82-1.84 billion, versus the consensus of $1.86 billion.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.